CoChat

Lactobacillus Bacteremia and Probiotics: A Review

Open access

The DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index; 37 of the 111 sources its claims cite were checked for support.

Abstract

Lactobacilli are widely found in nature, are commensal microbes in humans, and are commonly used as probiotics. Concerns about probiotic safety have arisen due to reports of bacteremia and other Lactobacillus-associated infections. We reviewed the literature for articles on the pathogenicity of Lactobacillus spp. bacteremia and reports of probiotics in these patients. Our aim is to review these articles and update the present knowledge on the epidemiology of Lactobacillus spp. bacteremia and determine the role of probiotics in Lactobacillus bacteremia. Lactobacillus bacteremia is infrequent but has a higher risk of mortality and risk factors, including severe underlying diseases, immune system suppression, admission to intensive care units, and use of central venous catheters. A variety of Lactobacillus species may cause bacteremia and may or may not be associated with probiotic exposure. To determine if oral probiotics are the source of these infections, the blood isolates and the oral probiotic strain(s) must be compared by sensitive identification methods. The prevalence of Lactobacillus bacteremia is infrequent but is more common in patients taking probiotics compared to those not taking probiotics. Three probiotics (Lacticaseibacillus rhamnosus GG, Lactiplantibacillus plantarum, and Lacticaseibacillus paracasei) were directly linked with blood isolates from bacteremia patients using molecular identification assays.

Overview

CoChat Summary

TL;DR

This review finds Lactobacillus bacteremia (LB) is infrequent but associated with high mortality and risk factors including severe underlying disease, immunosuppression, ICU admission, and central venous catheters. Probiotic strains are an infrequent source: only 23 of 75 reviewed LB cases had a blood isolate identical to the probiotic strain taken, with Lacticaseibacillus rhamnosus GG most commonly implicated.

Key findings

  • LB prevalence is low: 0.1–0.2% of blood culture isolates from hospitalized patients and 0.5% from immunocompromised patients; one hematopoietic cell transplant cohort reported 1.6 cases/100,000 patient days, and Finland averaged 0.29 cases/100,000 inhabitants/year from 1995–2000 despite increased Lcb. rhamnosus GG use.
  • Mortality is high but often attributed to underlying conditions: estimated at 30%; Salminen et al. found 26% mortality at one month and 48% at one year; Husni et al. found 44% died during hospitalization but only one death was directly attributable to LB; Franko et al. reported 23.7% case fatality by day 28 and 45% at one year.
  • Risk factors include severe underlying diseases (OR = 15.8 for mortality), while treatment with antibiotics effective in vitro was associated with lower mortality (OR = 0.22); in one review, 49% were in ICU, 40% had cancer, 37% immunosuppression, 29% central venous devices, and 39% had ≥2 risk factors.
  • Among 75 total LB cases reviewed, 23 had a blood isolate identical to the probiotic strain taken; three probiotics were directly linked by molecular identification: Lcb. rhamnosus GG, Lactiplantibacillus plantarum, and Lcb. paracasei. In one pediatric ICU study, 6/522 (1.1%) patients receiving Lcb. rhamnosus GG developed LB versus 2/21,652 (0.009%) not receiving it; in pediatric hematopoietic cell transplant patients, 6/34 (17.6%) given a probiotic developed LB, with three matched to the probiotic blend.

Methods

  • Literature review from 1980 to 2023 on Lactobacillus spp. bacteremia pathogenicity and probiotic reports in these patients.
  • Search terms included Lactobacillus, bacteremia, probiotics, risk factors, treatment, antibiotic susceptibilities, safety, epidemiology, sepsis, endocarditis, and infection.
  • Inclusion criteria were case reports, case series, observational studies, and reviews; exclusion criteria were non-Lactobacilli bacteremias, fungemias, or other diseases; references from reviews and published papers were also queried.

Limitations

  • The paper states that many reports attempting to link probiotic strains to LB isolates failed to prove correlation because of incomplete identification of strains; molecular identification of both the blood isolate and the probiotic strain is needed.
  • The paper states that clinical experience and clinical trials on optimal antibiotic treatments are lacking, and that more studies on length of hospital stay, healthcare-associated costs, and long-term surveillance of probiotic use and LB are warranted.
  • Evident from the text: this is a literature review without a described systematic search or meta-analysis, and findings depend on heterogeneous case reports, case series, and observational studies with variable identification methods and incomplete strain reporting; LB may also be underdiagnosed because lactobacilli are difficult to culture and identify and are often deemed contaminants.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/microorganisms11040896

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

24 Valid · 2 Not valid · 33 Not checked · 26 Own results and interpretations

44 more claims · 11 with their cited sources checked

Create a free account to see all 85 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 76 references

Research works printed but not linked: 1

  1. 2019, [Sepsis due to Lactobacillus reuteri in an extreme preterm newborn: Case report], Arch. Argent Pediatr., 117, e509

Cited by

Items 101–151 of 151

Metadata

Authors
Kullar, R., Goldstein, E. J. C., Johnson, S., & McFarland, L. V.
Affiliations
  • Expert Stewardship Inc., Newport Beach, CA 92663, USA
  • R.M. Alden Research Laboratory, Santa Monica, CA 90404, USA
  • Edward Hines, Jr. VA Hospital (US)
  • McFarland Consulting, Seattle, WA 98115, USA
Corresponding author
McFarland, Lynne V.
Venue
Microorganisms
Publisher
MDPI AG
Published
2023-03-30
Volume
11
Issue
4
Pages
896
ISSN
2076-2607 (ISSN-L)
OpenAlex
W4361274209
Cited by
156
References
80
Citations by year
2026: 47 · 2025: 52 · 2024: 47 · 2023: 10
FWCI
3.60
Type
journal article
Language
en
Open access
Locations
  • Microorganisms (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Bio-K+
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
Keywords
probiotics, probiotic safety, Lactobacillus rhamnosus GG, Lactobacillus plantarum, Lactobacillus paracasei, central venous catheters, immunosuppression, intensive care unit admission

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.